Correlation between development of restenosis and duration of antiaggregant treatment in patients undergoing carotid stent implantation

Purpose: In this study, we aimed to evaluate that is there any correlation between the early results of restenosis (including in stent thrombosis) and post-procedural usage of dual antiaggregant theraphy for 3 or 6 months in patients undergoing carotid stent implantation. Materials and methods: The study was carried out retrospective analysis of patients between the years of 2010 and 2016, in which 77 (32.5%) female and 160 (67.5%) male, aged between 51 and 88 with carotid stent implantation. Patients in this study were divided into three groups: those who were treated dual antiaggregant therapy for 3 months, 6 months and considered to be inadequate. Statistical analysis of restenosis (> 50% stenosis, accepted as significant stenosis) was performed using dual antiaggregant medication for 3 months or 6 months after the antiagregant medication failure was evaluated separately. Results: İn five (2.1%) of the patients had inadequate antiagregan medication. There were 166 patients (70%) who were used for 3 months and 66 patients (27.8%) were used for 6 months. Restenosis was detected in 22 (%9,2) patients in totally, 12 (%7,2) patients of which were treated for 3 months, 5 (%7,5) patients were treated for 6 months, and 5 (%100) patients in the cases with antiagregan medication failure. Patients was out of statistical analysis who had story of inadequate antiaggregant treatment. There was no statistically significant difference between two groups of patients with different antiaggregant treatment times (p> 0,999). There was also no difference between the two groups in terms of new developed neurological findings and the incidence of bleeding. Conclusion: There was no difference in restenosis between 3 months of dual antiaggregant therapy and 6 months of using. There is no difference in development of new neurological findings or bleeding complications of using the duration of the dual antiaggregant therapy. The important thing in antiagregant medication, looks like patient adaptation and antiagregan resistance. These data need to be evaluated with more extensive and comprehensive data analysis. Key words: Carotid stent implantation, Dual antiaggregant, Stent restenosis, Antiaggregant resistance.